ImaginAb’s proprietary minibody platform technology allows whole-body imaging of high-value molecular targets. 89Zr-Df-IAB22M2C, our lead compound currently in development, enables the non-invasive imaging of CD8+ T cells using standard Positron Emission Tomography (PET).

The ability to visualize CD8+ T cells in vivo before and after initiation of immunotherapy could lead to major advances in the understanding of local and systemic immune response in immune-oncology, and assist clinicians in improving treatment selection and monitoring of cancer patients.

ImaginAb is currently conducting its Phase II Baseline/On-Treatment clinical trial globally in collaboration with world-renowned Research Centers and Investigators

89Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients with Metastatic Solid Tumors Identifier: NCT03802123 – Phase II Baseline / On treatment CD8 Imaging